FAST NEWS: Zai Lab’s Loss Widens as R&D Costs Surge
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) on Thursday reported a $161 million net loss in the third quarter, 67% wider than its $96.41 million loss a year…
3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
RELATED ARTICLES
-
Innogen Pharma jostles for a slice of the weight-loss market
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
Lopal steers back towards profitability after tough two years
2465.HK 603906.SHG
-
BRIEF: Coolpad loss widens as hardware margins drop
2369.HK
